• Angiotensin (1-7): Applied Protocols and Research Advantages

  2026-06-27

  Angiotensin (1-7) unlocks robust anti-fibrotic and anti-inflammatory workflows, with high solubility and validated mechanistic targets for renal, metabolic, and neuroprotection research. This guide translates the latest microbiome-RAS interface insights into practical protocols, troubleshooting strategies, and advanced applications across model systems.

• Small-Molecule uPAR Inhibition Reduces Breast Cancer Metasta

  2026-06-26

  This study identifies and validates IPR-803, a small-molecule urokinase receptor inhibitor, as a direct disruptor of the uPAR–uPA interaction—a key driver of tumor invasion and metastasis. The work demonstrates both in vitro and in vivo efficacy in breast cancer models, providing a mechanistic foundation for next-generation anti-metastatic research.

• Maximizing Cancer Research with BCL-XL Inhibitor A-1155463

  2026-06-26

  A-1155463 empowers biomedical researchers to unravel apoptosis mechanisms and overcome drug resistance in BCL-XL-dependent tumor models. This guide delivers advanced workflows, troubleshooting strategies, and unique insights for selective BCL-XL inhibitor applications in cutting-edge cancer biology.

• 3-Aminobenzamide (PARP-IN-1): Optimizing PARP Inhibition Wor

  2026-06-25

  3-Aminobenzamide (PARP-IN-1) stands out as a potent, low-toxicity PARP inhibitor that enables precise modulation of poly (ADP-ribose) polymerase activity in cellular and disease models. This article details advanced protocols, troubleshooting guidance, and novel insights from recent virology research, equipping scientists for high-reproducibility studies ranging from oxidative stress to diabetic nephropathy.

• DNA Damage Drives Selective CUX2 Neuron Loss in Neuroinflamm

  2026-06-25

  This study uncovers how DNA damage accumulation leads to selective loss of CUX2-expressing cortical neurons during neuroinflammation, especially in the context of multiple sclerosis. The findings advance understanding of cell-type-specific neurodegeneration mechanisms and highlight the importance of DNA repair pathways in neuronal resilience.

• EPZ5676: Redefining DOT1L Inhibition in Epigenetic Leukemia

  2026-06-24

  Explore how EPZ5676, a potent DOT1L inhibitor, enables precise H3K79 methylation inhibition and advances MLL-rearranged leukemia research. This article uniquely dissects assay design, selectivity mechanisms, and translational applications for epigenetic modulation.

• Tomivosertib Suppresses Ectopic Activity in Human DRG Neuron

  2026-06-23

  This study provides the first direct evidence that Tomivosertib, a selective MNK1/2 inhibitor, reversibly suppresses spontaneous activity in human dorsal root ganglion (DRG) neurons associated with neuropathic pain. These findings highlight the translational potential of MNK-eIF4E pathway inhibition for addressing pain mechanisms in human sensory neurons.

• U0126-EtOH: Strategic MEK1/2 Inhibition for Translational Im

  2026-06-23

  This thought-leadership article explores the strategic role of U0126-EtOH, a selective MEK1/2 inhibitor, in advancing translational research targeting the MAPK/ERK pathway. Bridging mechanistic insights with real-world protocol guidance, it highlights applications in neuroprotection, inflammation, and the emerging paradigm of paraptosis in cancer. Critical literature, including recent discoveries in APL cell death, is integrated alongside practical advice for experimental design, positioning U0126-EtOH as a foundational tool for next-generation discoveries.

• Pazopanib (GW-786034) for Cancer Research: Protocols & Preci

  2026-06-22

  Pazopanib (GW-786034) stands out as a versatile multi-targeted RTK inhibitor, enabling researchers to dissect angiogenesis and tumor growth suppression with robust in vitro and in vivo models. This guide translates cutting-edge findings—such as those from ATRX-deficient glioma studies—into actionable workflows, troubleshooting strategies, and comparative insights for advanced cancer research.

• Phosbind Biotin: Dinuclear Metal Complex for Phosphorylation

  2026-06-22

  Phosbind Biotin leverages advanced dinuclear metal complex phosphate binding for highly sensitive, sequence-independent detection of phosphorylated proteins in Western Blot. Its streamlined workflow and antibody-free specificity unlock robust protein phosphorylation analysis, particularly where traditional phospho-specific antibodies fall short.

• APEX2 Regulates TERT Expression in Human Embryonic Stem Cell

  2026-06-21

  This study reveals that APEX2, a DNA repair enzyme, is essential for efficient TERT expression in human embryonic stem cells and melanoma cells. These findings provide new mechanistic insight into telomerase regulation, linking DNA repair processes to gene expression control, with implications for stem cell maintenance, aging, and cancer biology.

• Anlotinib Hydrochloride: Multi-Target TKI Workflows in Cance

  2026-06-20

  Anlotinib hydrochloride stands out as a potent multi-target tyrosine kinase inhibitor with superior anti-angiogenic efficacy. This article provides a hands-on guide to designing, optimizing, and troubleshooting angiogenesis and cancer proliferation assays using Anlotinib, highlighting its unique advantages for translational research.

• APEX2 Regulates TERT Expression in Human Embryonic Stem Cell

  2026-06-19

  This study identifies a novel role for APEX2 in regulating TERT expression in human embryonic stem cells (hESC) and melanoma cells. The findings reveal that APEX2, but not APEX1, is essential for efficient telomerase activity, with implications for stem cell maintenance, aging, and cancer biology.

• PF-562271 HCl: Uncovering FAK/Pyk2 Inhibition for Tumor Immu

  2026-06-19

  Explore how PF-562271 HCl, a potent FAK/Pyk2 inhibitor, offers new insights into tumor immunomodulation and cancer research. This article uniquely bridges advanced kinase signaling with emerging immuno-oncology strategies.

• NVP-BGJ398 Phosphate: Expanding FGFR Inhibition to Rare Skel

  2026-06-18

  NVP-BGJ398 phosphate, a potent pan-FGFR inhibitor, is reshaping translational research by bridging oncology advances with new therapeutic potential in rare skeletal disorders. This article provides mechanistic insight, critical protocol guidance, and strategic foresight for researchers seeking to leverage FGFR pathway inhibition in both cancer and SLC26A2-related chondrodysplasia models, substantiated by the latest in vivo evidence.

15920 records 1/1062 page Next 12345 下5页 Last page